Immune ablation and stem-cell therapy in autoimmune disease: Clinical experience
AUTOR(ES)
Tyndall, Alan
FONTE
BioMed Central
RESUMO
In the past 5 years, around 350 patients have received haematopoietic stem cell (HSC) transplantation for an autoimmune disease, with 275 of these registered in an international data base in Basel under the auspices of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation(EBMT). Most patients had either a progressive form of multiple sclerosis (MS; n = 88) or scleroderma (now called systemic sclerosis; n = 55). Other diseases were rheumatoid arthritis (Ra n = 40), juvenile idiopathic arthritis (JIA; n = 30), systemic lupus erythematosus (SLE; n = 20), idiopathic thrombocytopenic purpura (ITP; n = 7) and others. The procedure-related mortality was around 9%, with between-disease differences, being higher in systemic sclerosis and JIA and lower in RA (one death only). Benefit has been seen in around two-thirds of cases. No one regimen was clearly superior to another, with a trend toward more infectious complications with more intense regimens. Prospective, controlled randomized trials are indicated and being planned.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=130009Documentos Relacionados
- Immune ablation and stem-cell therapy in autoimmune disease: Introduction
- Immune ablation and stem-cell therapy in autoimmune disease: Experimental basis for autologous stem-cell transplantation
- Immune ablation and stem-cell therapy in autoimmune disease: Immunological reconstitution after high-dose immunosuppression and haematopoietic stem-cell transplantation
- Stem-cell therapy for hearing loss: are we there yet?
- Clonal analysis of hematopoietic stem-cell differentiation in vivo.
